0001209191-23-044031.txt : 20230801
0001209191-23-044031.hdr.sgml : 20230801
20230801173254
ACCESSION NUMBER: 0001209191-23-044031
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230801
FILED AS OF DATE: 20230801
DATE AS OF CHANGE: 20230801
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Andriole Michael T.
CENTRAL INDEX KEY: 0001698751
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35867
FILM NUMBER: 231132970
MAIL ADDRESS:
STREET 1: C/O ENDOCYTE, INC.
STREET 2: 3000 KENT AVENUE, SUITE A1-100
CITY: WEST LAFAYETTE
STATE: IN
ZIP: 47906
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CHIMERIX INC
CENTRAL INDEX KEY: 0001117480
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330903395
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100
CITY: DURHAM
STATE: NC
ZIP: 27713
BUSINESS PHONE: 919.806.1074
MAIL ADDRESS:
STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100
CITY: DURHAM
STATE: NC
ZIP: 27713
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-08-01
0
0001117480
CHIMERIX INC
CMRX
0001698751
Andriole Michael T.
2505 MERIDIAN PARKWAY, SUITE 100
DURHAM
NC
27713
1
1
0
0
President and CEO
0
Common Stock
2023-08-01
4
A
0
25000
1.19
A
382015
D
Stock Option (Right to Buy)
1.19
2023-08-01
4
A
0
150000
0.00
A
2033-07-31
Common Stock
150000
150000
D
The shares being reported are being issued pursuant to restricted stock unit awards ("RSUs"), each one of which represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the RSUs will vest in equal annual installments over a four year period from 08/01/2023, so long as the Reporting Person continues to provide services to the Issuer.
The shares subject to the nonstatutory stock option ("Option"), under Chimerix, Inc.'s 2013 Equity Incentive Plan, will vest over a period of four years so long as the Reporting Person continues to provide services to the Issuer, with 25% of the shares subject to the Option vesting on 08/01/2024 and the balance of shares vesting in 36 equal monthly installments over the remaining three years.
/s/ Michael Alrutz, Attorney-in-Fact
2023-08-01